| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-19167SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-46892SS | |||
| Azide and BSA Free | NBP2-80829 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24877SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-27399 | |||
| Azide and BSA Free | NBP2-27399SS | |||
| BSA Free | NB100-56749SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-648SS | |||
| Azide and BSA Free | NBP2-81006 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-2289SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51691SS | |||
| Azide and BSA Free | NBP2-80611 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-41568SS | |||
| Conjugate | Catalog # | Availability | Size | Price |
|---|---|---|---|---|
| Alexa Fluor Plus 405 | NBP1-47470AFP405 | |||
| Alexa Fluor Plus 488 | NBP1-47470AFP488 | |||
| Alexa Fluor Plus 555 | NBP1-47470AFP555 | |||
| Alexa Fluor Plus 594 | NBP1-47470AFP594 | |||
| Alexa Fluor Plus 647 | NBP1-47470AFP647 | |||
| Alexa Fluor Plus 680 | NBP1-47470AFP680 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-47470SS | |||
| Azide and BSA Free | NBP2-80757 | |||
![Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.](http://images.novusbio.com/fullsize/LC3A-Antibody-Western-Blot-NBP1-19167-img0012.jpg "<b>Biological Strategies Validation. </b>Western Blot: LC3A Antibody [NBP1-19167] - Total protein from HeLa and Neuro2A cells treated with or without 50 uM chloroquine for 24 hours was separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-LC3A in 1% non-fat milk in TBST and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the detection LC3 II upon chloroquine treatment.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: LC3A Antibody [NBP1-19167] - LC3/MAP1 [NBP1-19167] - LC3 antibody was tested in HeLa cells with Dylight 488 (green). Cells were treated overnight with 50 uM chloroquine to induce autophagosome formation. Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-19167-img0013.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse brain using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the cells with highest positivity in various neurons.](http://images.novusbio.com/fullsize/LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0014.jpg)
![Western Blot: LC3/MAP1LC3A Antibody [NBP1-19167] - Human brain lysate.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Western-Blot-NBP1-19167-img0004.jpg)
![Immunohistochemistry-Paraffin: LC3A Antibody [NBP1-19167] - Analysis of a FFPE tissue section of mouse liver using LC3 antibody at 1:300 dilution. The signal was developed using HRP-labelled secondary antibody and DAB reagent, and the sections/nuclei were further counterstained with hematoxylin. Note the diffused cytoplasmic staining of LC3 in all of the hepatocytes and other liver cells.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Immunohistochemistry-Paraffin-NBP1-19167-img0010.jpg)
![Simple Western: LC3A Antibody [NBP1-19167] - Image shows a specific band for LC3 in 0.5 mg/mL of Neuro2A lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/LC3-MAP1LC3A-Antibody-Simple-Western-NBP1-19167-img0009.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0012.jpg "<b>Genetic Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT decreases p53mut stability. T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 i1/4M), Nutlin3A (5 i1/4M) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: p14ARF/CDKN2A Antibody [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo and synergizes with ionizing radiation to inhibit tumor growth( Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). Sections of PSN1 xenografts and in-vitro PSN1 cells fixed and stained with anti-NPM (red) and anti-p14ARF (green). Image collected and cropped by Citeab from the following publication (AKT regulates NPM dependent ARF localization and p53mut stability in tumors. Oncotarget (2014)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0028.jpg "<b>Genetic Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis shows lysates of HeLa human cervical epithelial carcinoma parental cell line and LC3B knockout HeLa cell line (KO) untreated (-) or treated (+) with 50 uM Chloroquine for 18 hours. PVDF (Polyvinylidene difluoride) membrane was probed with 2.0 ug/mL of Rabbit Anti-Human/Mouse/Rat LC3B Monoclonal Antibody (1251A) [Catalog # NBP2-46892] followed by HRP-conjugated Anti-Rabbit IgG Secondary Antibody (Catalog# HAF008). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. GAPDH is shown as a loading control. This experiment was conducted under reducing conditions.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - LC3B was detected in immersion fixed Chloroquine treated Hela cells (left) but was not detected in LC3B knockout Hela cells (right) using rabbit anti-human LC3B monoclonal antibody (1251A) [Catalog #NBP2-46892] at 0.3 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rabbit IgG Secondary Antibody (red; Catalog # NL004) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Knockout-Validated-NBP2-46892-img0036.jpg)
![Western Blot: LC3B Antibody (1251A) [NBP2-46892] - The expression of LC3B in rat tissue. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0034.jpg)
![<b>Biological Strategies Validation. </b>Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - Jurkat cells were either untreated (A) or treated with 50uM chloroquine for 24 hours (B). An intracellular stain was performed with anti-LC3B (1251A) antibody [Catalog # NBP2-46892] (blue) and a matched isotype control [Catalog # MAB1050] (orange). Cells were fixed with 4% paraformaldehyde, following fixation, cells were permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by rabbit IgG APC-conjugated secondary antibody (F0111, R&D Systems).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0026.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Effects of PDTC on LC3 on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level and given in relative arbitrary units. LC3-II increased in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II compared with vehicle-treated rats. Data were expressed as mean +/- SEM, n = 6/group. *P < 0.05 vs sham-operated group. # P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation and puncture. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/26067996) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0038.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with Chloroquine for 24 hours prior to fixation, permeabilization and incubation with anti- [Catalog # NBP2-46892] and anti tubulin (NB100-690) antibodies. Image enlargement shows the accumulation of LC3 (green) on autophagosomes in response to Chloroquine treatment. Tubulin staining is shown in red and DNA is counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0032.jpg)
![Immunohistochemistry-Paraffin: LC3B Antibody (1251A) [NBP2-46892] - IHC (Immunohistochemical) analysis of a formalin fixed and paraffin embedded tissue section of normal mouse brain using rabbit monoclonal LC3B (1251A) antibody [Catalog # NBP2-46892] at 1:100 dilution with HRP-DAB detection. The antibody generated a weak diffused cytoplasmic staining in most of the cells but some cells, especially within empty areas on the section, showed punctate signal also which signifies the presence of autophagy in those areas.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunohistochemistry-Paraffin-NBP2-46892-img0033.jpg)
![Flow Cytometry: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells untreated or treated with 50 uM chloroquine for 24h. Image from the Alexa Fluor 405 version of this antibody.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Cytometry-NBP2-46892-img0037.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Analysis shows lysates of HeLa human cervical epithelial carcinoma cell line untreated (-) or treated (+) with Chloroquine. PVDF membrane was probed with 0.2 ug/mL rabbit anti-LC3B monoclonal Antibody (1251A) (Catalog # NBP2-46892, Novus Biologicals), followed by 1:2000 dilution of goat anti-rabbit IgG secondary antibody. A specific band was detected for LC3B at a molecular weight of approximately 15 kDa in CQ treated NIH-3T3 and PC12 cell lines.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot analysis using HeLa cells treated with (+) or without (-) Chloriquine (CQ). A specific band was detected for LC3B at a molecular weight of approximately 15 kDa.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0010.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: LC3B Antibody (1251A) [NBP2-46892] - Western Blot image of monoclonal anti-LC3B Antibody (Clone 1251D) [Catalog # NBP2-46892]. HeLa and Neuro2A cells were treated with or without 50 uM chloroquine for 24 hours as indicated. Whole cell protein was then separated on a 4-15% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane for 30 min and blocked in 5% non-fat milk in TBST (Tris-buffered saline, 0.1% Tween 20). The membrane was probed with 2 ug/ml anti-LC3B Antibody in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence. Note the accumulation of LC3B II upon chloroquine treatment. Bands for LC3 were detected at a molecular weight of approximately 15 kDa in treated HeLA cells, and both treated and untreated Neuro2A cells.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Western-Blot-NBP2-46892-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: LC3B Antibody (1251A) [NBP2-46892] - HeLa cells were treated with 50 uM Chloroquine for 24 hour prior to fixation in 10% buffered formalin for 10 min. Cells were permeabilized in 0.1% Triton X-100 and incubated with 20 ug/ml anti- [Catalog # NBP2-46892] and 1:500 anti-tubulin [Catalog # NB100-690] for 1 h at room temperature. LC3B reactivity (green) was detected with ant-rabbit Dylight 488 and tubulin (red) with anti-mouse Dylight 550. Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunocytochemistry-Immunofluorescence-NBP2-46892-img0030.jpg)
![Flow (Intracellular): LC3B Antibody (1251A) [NBP2-46892] - HeLa human cervical epithelial carcimoa cell line either treated with 50 uM chloroquine for 24 hours (filled histogram) or untreated (open histogram) was stained with Rabbit anti-Human LC3B Alexa Fluor 647 conjugated monoclonal antiobdy (1251A) [Catalog # NBP2-46892AF647]. To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation and Permeabilization Buffer Kit (FC012-NOV).](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Flow-Intracellular-NBP2-46892-img0025.jpg)
![Immunoprecipitation: LC3B Antibody (1251A) [NBP2-46892] - Western blot analysis of LC3 immunoprecipitation. 10 ug of monoclonal anti-LC3B antibody (clone 1251A) [Catalog # NBP2-46892] was used to immunoprecipitate LC3 from 200 ug of total protein from HeLa cells treated with or without 50 uM chloroquine for 24 h. Antibody-protein was captured by magnetic protein A/G beads, washed and subjected to SDS-PAGE on a 4-15% gel. Protein was transferred to 0.2 um PVDF membrane and probed with 2 ug/ml anti-LC3B (NB100-2220) and detected with an anti-rabbit HRP conjugated secondary antibody using chemiluminescence. The detection of LC3 at a molecular weight of approximately 12 kDa and the antibody heavy chain (Ab Hc) at a molecular weight of approximately 50 kDa is indicated.](http://images.novusbio.com/fullsize/LC3B-Antibody-1251A-Immunoprecipitation-NBP2-46892-img0031.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - Effects of PDTC on LC3 (a), Beclin1 (b), LAMP-1 (c), & Rab7 (d) on the hippocampus of rats harvested 12 h after CLP. Values of protein data are normalized to actin level & given in relative arbitrary units. LC3-II increased while Beclin1, Rab7, & LAMP-1 declined in CLP rats receiving vehicle or PDTC compared with those in sham-operated rats. PDTC + CLP rats showed an increase in LC3-II, Beclin1, Rab7, & LAMP-1 compared with vehicle-treated rats. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. #P < 0.05 vs 12 h or Veh + CLP group. PDTC pyrrolidine dithiocarbamate, LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-310202415291956.jpg)
![Western Blot: LC3B Antibody (1251A) - BSA Free [NBP2-46892] - a LC3 in brains harvested 3, 6, 12, 24, & 48 h after CLP. b Immunofluorescence for LC3 in neurons after CLP injury. Values of protein data were related to signals obtained from actin protein & given as relative arbitrary units. LC3-II significantly increased in CLP rats at 6, 12, 24, & 48 h after surgery compared with sham-operated rats. Three-color staining for anti-LC3 antibody (green), NeuN (red), & DAPI (blue) showed that a staining pattern changes from largely diffuse to predominantly punctate & cytoplasmic in hippocampal neurons after CLP. Data were expressed as mean ± SEM, n = 6/group. *P < 0.05 vs sham-operated group. LC-3 microtubule-associated protein light chain-3, CLP cecal ligation & puncture, DAPI 4,6-diamidino-2-phenylindole Image collected & cropped by CiteAb from the following publication (//jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-015-0336-2), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-46892_rabbit-monoclonal-lc3b-antibody-1251a-31020241612245.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: LOX Antibody [NBP2-24877] - Analysis of mouse ear lysate when LOX antibody (NBP2-24877) was used at 1:1000. The band shown is the expected inactive 50 kD proenzyme.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NBP2-24877-img0006.jpg "Western Blot: LOX Antibody [NBP2-24877] - Analysis of mouse ear lysate when LOX antibody (NBP2-24877) was used at 1:1000. The band shown is the expected inactive 50 kD proenzyme.")
![Immunocytochemistry/Immunofluorescence: LOX Antibody [NBP2-24877] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-LOX (NBP2-24877) at a 1:200 dilution overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Alpha tubulin was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-24877-img0007.jpg)
![Immunohistochemistry-Paraffin: LOX Antibody [NBP2-24877] - Analysis of LOX in formalin-fixed, paraffin-embedded mouse skin using an isotype control (top) and NBP2-24877 (bottom) at 1:100.](http://images.novusbio.com/fullsize/LOX-Antibody-Immunohistochemistry-Paraffin-NBP2-24877-img0002.jpg)
![Western Blot: LOX Antibody [NBP2-24877] - Analysis of LOX in A) human skin and B) mouse ear skin lysate using NBP2-24877 at 1:500. Goat anti-rabbit IgG HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/LOX-Antibody-Western-Blot-NBP2-24877-img0001.jpg)
![Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Total protein from mouse 3T3 cells treated with and without PDGF (50 ng/mL) for the indicated times was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-AKT1 (NBP2-01725) and 2 ug/mL pS473 AKT1 in 1% BSA in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence. Note the detection of phosphorylated AKT1 in response to PDGF treatment compared to total AKT1 protein.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Western-Blot-NB100-56749-img0014.jpg "<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Total protein from mouse 3T3 cells treated with and without PDGF (50 ng/mL) for the indicated times was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-AKT1 (NBP2-01725) and 2 ug/mL pS473 AKT1 in 1% BSA in TBST and detected with an anti-mouse HRP secondary antibody using chemiluminescence. Note the detection of phosphorylated AKT1 in response to PDGF treatment compared to total AKT1 protein.")
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - WB of phospho AKT using phospho AKT antibody at 2 ug/mL against untreated (lane 1) and PDGF treated (lane 2) NIH-3T3 lysate. HRP conjugated secondary antibody and ECL substrate solution were used for this test. Image using the Azide and BSA Free form of this antibody.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Western-Blot-NB100-56749-img0015.jpg)
![Immunohistochemistry-Paraffin: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - IHC analysis of an FFPE human breast carcinoma tissue section using 1:250 dilution of phospho Ser473 AKT1 antibody (clone 104A282) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of phosphor-AKT (Ser-473) in the cancer cells as well as the stromal cells. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Paraffin-NB100-56749-img0009.jpg)
![Immunohistochemistry-Frozen: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - Rat mammary carcinoma tissue section stained with AKT1 [p Ser473] Antibody (104A282). IHC-Fr image submitted by a verified customer review.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Frozen-NB100-56749-img0016.jpg)
![Immunohistochemistry-Paraffin: AKT1 [p Ser473] Antibody (104A282) [NB100-56749] - IHC analysis of an FFPE human breast carcinoma tissue section using 1:250 dilution of pSer473 AKT1 antibody (clone 104A282) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of phosphor-AKT (Ser-473) in the cancer cells as well as the stromal cells. Some cancer cells depicted nuclear stianing also. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/AKT1-p-Ser473-Antibody-104A282-Immunohistochemistry-Paraffin-NB100-56749-img0010.jpg)
![EZH2/HMGA2 regulates the PI3K/AKT signaling. MI rats were subjected to injection of EZH2-OE or EZH2-NC (MI + MSC-EXO + EZH2 NC/EZH2 OE) and EZH2-OE + HMGA2-OE or EZH2-OE + HMGA2-NC. A HMGA2 protein expression in myocardial tissues in response to EZH2-OE + HMGA2-OE examined using western blot (Additional file 5: Fig. S5). B Weight change in rats after EZH2-OE + HMGA2-OE treatment. C Changes in HMI in rats after EZH2-OE + HMGA2-OE treatment. D Measurement of Dd, Sd, and LVEF by echocardiography at 2 weeks after LAD in rats. E Measurement of LVMI by echocardiography in rats. F KEGG pathway analysis of gene enrichment pathways [29]. G Changes in PI3K/AKT pathway in rat myocardium examined using western blot (Additional file 6: Fig. S6). All data are expressed as mean +/- SD (n = 6/group, *p < 0.05 vs. Sham, DMSO, MI + MSC-EXO + EZH2-NC or EZH2-OE + HMGA2-NC group determined by unpaired t test or one-way ANOVA) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35264108), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-56749_mouse-monoclonal-akt1-p-ser473-antibody-104a282-western-blot-13220261820240.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0004.jpg "Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC analysis of VEGF in fetal sheep brain tissue. Image courtesy of anonymous customer review.")
![Western Blot: VEGF Antibody (VG76e) [NB100-648] - Analysis of VEGF in human kidney protein (30ug).](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Western-Blot-NB100-648-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: VEGF Antibody (VG76e) [NB100-648] - Immunofluorescent analysis of VEGF using NB100-648. This image submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunocytochemistry-Immunofluorescence-NB100-648-img0007.jpg)
![Immunohistochemistry-Paraffin: VEGF Antibody (VG76e) [NB100-648] - IHC-P analysis of VEGF in sheep tonsil using NB100-648. This image was submitted through a verified customer review.](http://images.novusbio.com/fullsize/VEGF-Antibody-VG76e-Immunohistochemistry-Paraffin-NB100-648-img0006.jpg)
![Western Blot: Mouse Monoclonal VEGF Antibody (VG76e) [NB100-648] - Bone lysate homogenate from goats. SDS-PAGE with 0.3 mg of total protein from the homogenate per well. VEGF, NB100-648, was used at a dilution of 1:1000 in TBS Tween and 5% milk powder. The protein was labeled at 40 kDa. Quantification of VEGFA in bone graft in the tibia of intrailiac cellularized goats at different times compared with tibial autograft and untreated bone defect. Evaluation of pre-cellularized graft in iliac crest in the treatment of bone defects in the tibia of goats. G1: cellularized graft for 4 weeks applied to tibial bone defect, G2: cellularized graft for 6 weeks applied to tibial bone defect, G3: cellularized graft for 8 weeks applied to tibial bone defect, G4: tibial autograft and G5: untreated bone defect. All groups were evaluated 120 days after graft implantation. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nb100-648_mouse-monoclonal-vegf-antibody-vg76e-western-blot-2952025142053..jpg)
![Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/AHR-Antibody-Knockdown-Validated-NB100-2289-img0014.jpg "<b>Genetic Strategies Validation. </b>Western Blot: AHR Antibody [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha. Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) and western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean +/- SD of two independent experiments performed in three replicates. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-020-58051-1), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: AHR Antibody [NB100-2289] - Staining of Aryl hydrocarbon Receptor in mouse prostate.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunohistochemistry-NB100-2289-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-AHR at 5 ug/mL overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0012.jpg)
![Western Blot: AHR Antibody [NB100-2289] - Detection of AhR in mouse liver cytosol using NB 100-2289.](http://images.novusbio.com/fullsize/AHR-Antibody-Western-Blot-NB100-2289-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - HepG2 cells were fixed for 10 minutes using 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti-AHR at 1 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0015.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U937 cells with NB100-2289 (blue) and a matched isotype control NBP2-24891 (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0017.jpg)
![Immunocytochemistry/Immunofluorescence: AHR Antibody [NB100-2289] - Aryl hydrocarbon Receptor antibody was tested in HeLa cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/AHR-Antibody-Immunocytochemistry-Immunofluorescence-NB100-2289-img0010.jpg)
![Flow Cytometry: AHR Antibody [NB100-2289] - An intracellular stain was performed on U-87 cells with AHR Antibody NB100-2289B (blue) and a matched isotype control (orange). Both antibodies were conjugated to Biotin. Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Streptavidin - R-Phycoerythrin Protein (2012-1000, Novus Biologicals).](http://images.novusbio.com/fullsize/AHR-Antibody-Flow-Cytometry-NB100-2289-img0013.jpg)
![Simple Western: AHR Antibody [NB100-2289] - Image shows a specific band for Aryl hydrocarbon receptor in 0.5 mg/mL of HepG2 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/AHR-Antibody-Simple-Western-NB100-2289-img0011.jpg)
![Western Blot: AHR Antibody - BSA Free [NB100-2289] - Activation of AHR/Nrf2 pathway by PFT-alpha . (A) qPCR to detect mRNA level of CYP1A1, NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells (upper part) & T47D cells (lower part). Relative expression level of CYP1A1 is shown in log2 scale; relative expression level of NQO1, HO1 & TRXR1 are shown as fold change, both normalized with DMSO treatment. All values represent the mean ± SD of two times independent experiments performed in three replicates. (B) Knock-down efficiency of AHR siRNA as detected by qPCR (upper part) & western blot (lower part). Relative expression level is shown as fold change normalized to scramble siRNA. All values represent the mean ± SD of two independent experiments performed in three replicates. (C) DCF-DA staining of ROS levels upon doxorubicin treatment (1 µM, 8 h) with or without PFT-alpha (20 µM, 12 h pre-treatment) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. For quantification of ROS levels (lower panel), the values are reported as percentage relative to DMSO treatment group. (D) qPCR to detect mRNA level of Nrf2 targets NQO1, HO1 & TRXR1 upon 20 h PFT-alpha treatment (20 µM) in MCF7 p53KO cells transfected with scramble siRNA & siAHR. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31974452), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-2289_rabbit-polyclonal-ahr-antibody-3102024165720.jpg)
![Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Western-Blot-NBP1-51691-img0006.jpg "Western Blot: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Carbonic Anhydrase IX mouse antibody against Hela (1) and A549 (2) cell lysates. Bands were detected at a molecular weight of approximately 50 kDa in both cell lines.")
![Immunohistochemistry-Paraffin: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Paraffin-embedded lung tissues (left) and colonic tissues (right) using Carbonic Anhydrase IX mouse antibody with DAB staining.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunohistochemistry-Paraffin-NBP1-51691-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) - BSA Free [NBP1-51691] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.05% Triton X-100 in PBS for 5 minutes. The cells were incubated with Carbonic Anhydrase IX/CA9 Antibody [2D3] (NBP1-51691) at 2ug/ml overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0012.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - A surface stain was performed on A431 cells with Carbonic Anhydrase IX/CA9 NBP1-51691 (blue) and a matched isotype control NBP2-27287 (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by DyLight488-conjugated anti-mouse secondary antibody.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Mouse choroid stained with anti-Carbonic Anhydrase IX antibody. ICC/IF image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Immunocytochemistry-Immunofluorescence-NBP1-51691-img0011.jpg)
![Flow Cytometry: Carbonic Anhydrase IX/CA9 Antibody (2D3) [NBP1-51691] - Analysis of NTERA-2 cells using Carbonic Anhydrase IX mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/Carbonic-Anhydrase-IX-CA9-Antibody-2D3-Flow-Cytometry-NBP1-51691-img0007.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0010.jpg "Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Analysis of HIF-2 alpha in human endometrium using. Donkey anti-mouse Alexa Fluor 488 secondary antibody was used. Image from verified customer review. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]")
![<b>Biological Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - WNT11 is induced by hypoxia or hypoxic mimetics in different cell types. Immunoblot analyses of HeLa cells under normal air or hypoxia for 24 hrs. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Western-Blot-NB100-902HIF2-img0012.jpg)
![Simple Western: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Lane view shows a specific band for HIF-2 alpha in 0.5 mg/ml of Hypoxic HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Simple-Western-NB100-902HIF2-img0009.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - HIF-1alpha is the predominant transcriptional regulator of WNT11 expression during hypoxia. EMSCs isolated from the indicated mouse genotypes were infected with lentivirus expressing GFP or Cre recombinase. Non-infected cells and GFP infected cells served as controls. Immunoblot analyses of EMSCs derived from the indicated genotypes treated with 0.1 mM DMOG for 24 hrs. Attenuated WNT11 expression in Hif-1alpha KO EMSCs (lenti-Cre infected Hif-1af/f). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/srep21520) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Knockout-Validated-NB100-902HIF2-img0013.jpg)
![<b>Orthogonal Strategies Validation. </b>Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Formalin-fixed paraffin-embedded tissue sections of human placenta were probed for HIF-2 alpha/EPAS1 mRNA (ACD RNAScope Probe, catalog #410598; Fast Red chromogen, ACD catalog # 322750). Adjacent tissue section was processed for immunohistochemistry using Rabbit Polyclonal (Novus Biologicals catalog # NB100-122) at 1:100 dilution with one-hour incubation at room temperature followed by incubation with anti-rabbit IgG VisUCyte HRP Polymer Antibody (Catalog # VC003) and DAB chromogen (yellow-brown). Tissue was counterstained with hematoxylin (blue). Specific staining was localized to trophoblastic cells. HIF-2 alpha/EPAS1 Antibody [NB100-122]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0014.jpg)
![Immunohistochemistry: HIF-2 alpha/EPAS1 Antibody Pack [NB100-902HIF2] - Normal ganglia 1 (NG1), normal ganglia 2 (NG2) and IDH-mutant (IDH). Sporadic PGL (Spo. PGL). HIF2 alpha staining. Image collected and cropped by CiteAb from the following publication (//doi.org/10.1371/journal.pone.0127471) licensed under a CC-BY license. HIF-2 alpha/EPAS1 Antibody (ep190b) [NB100-132]](http://images.novusbio.com/fullsize/HIF-2-alpha-EPAS1-Antibody-Pack-Immunohistochemistry-NB100-902HIF2-img0011.jpg)
![Western Blot: LOX propeptide Antibody [NB110-41568] - Detection of LOPP in MC3T3-E1 cell lysate.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Western-Blot-NB110-41568-img0012.jpg "Western Blot: LOX propeptide Antibody [NB110-41568] - Detection of LOPP in MC3T3-E1 cell lysate.")
![Immunohistochemistry: LOX propeptide Antibody [NB110-41568] - LOX-PP was over-expressed in the vascular wall and in VSMC from TgLOX mice. (a) Representative immunohistochemical analysis showing LOX-PP staining (brown color) in aorta from both wild-type and TgLOX mice. The indicated areas are shown at high magnification (bars = 20 um). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-018-31312-w) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Immunohistochemistry-NB110-41568-img0017.jpg)
![Western Blot: LOX propeptide Antibody - BSA Free [NB110-41568] - LOX propeptide Antibody [NB110-41568] - Human VSMC were transduced with a lentiviral vector encoding for full-length LOX (pLOX; black bars), LOX-PP (pLOX-PP; grey bars) or with the corresponding empty vector (pLVX; V; white bars). (a) Immunoblots corresponding to mature LOX (mLOX; left panel) & LOX-PP (right panel). The position of the pro-enzyme (ProLOX, right panel), detected with the antibody against the propeptide. GAPDH was analyzed as a loading control. Displayed blots are not cropped from different gels or different parts of the same gel. Representative immunoblots from 3 independent experiments were shown. Image collected & cropped by Cite Ab from the following publication (//pubmed.ncbi.nlm.nih.gov/30185869/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Western-Blot-NB110-41568-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: LOX propeptide Antibody [NB110-41568] - HepG2 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton-X100. The cells were incubated with anti-LOX propeptide at 5 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Immunocytochemistry-Immunofluorescence-NB110-41568-img0015.jpg)
![Western Blot: LOX propeptide Antibody [NB110-41568] - Total protein from human and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 0.5 ug/ml anti-LOX propeptide in block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Western-Blot-NB110-41568-img0014.jpg)
![Immunohistochemistry-Paraffin: LOX propeptide Antibody [NB110-41568] - IHC analysis of a formalin fixed paraffin embedded tissue section of mouse intestine using 1:200 dilution of rabbit anti- LOX propeptide (LOX-PP) antibody. The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This LOX-PP antibody generated a strong cytoplasmic staining in the epithelial and other cells with a majority of the signal localizing to luminal end of columner epithelial cells. There appears to be some nuclear positivity also which might be a nuclear variant of LOX-PP.](http://images.novusbio.com/fullsize/LOX-propeptide-Antibody-Immunohistochemistry-Paraffin-NB110-41568-img0011.jpg)
![Immunohistochemistry: LOX propeptide Antibody - BSA Free [NB110-41568] - Mature LOX & LOX-PP were over-expressed in the vascular wall & in VSMC from TgLOX mice. (a) Representative immunohistochemical analysis showing LOX & LOX-PP staining (brown color) in aorta from both wild-type & TgLOX mice. The indicated areas are shown at high magnification (bars = 20 µm). (b,c) Mature LOX & LOX-PP protein levels were determined by Western-blot in VSMC supernatants from these animals. The position of the pro-enzyme (ProLOX), mature LOX (mLOX) & LOX-PP forms are indicated. GAPDH was analyzed as loading control. Representative immunoblots from 3 independent experiments were shown. WT: wild-type; Tg: TgLOX. Displayed blots are not cropped from different gels or different parts of the same gel & images conform the digital image & integrity policies of the journal. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30185869), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-41568_rabbit-polyclonal-lox-propeptide-antibody-3102024162492.jpg)
![Western Blot: LOX propeptide Antibody - BSA Free [NB110-41568] - Over-expression of LOX-PP did not affect VSMC proliferation. Human VSMC were transduced with a lentiviral vector encoding for full-length LOX (pLOX; black bars), LOX-PP (pLOX-PP; grey bars) or with the corresponding empty vector (pLVX; V; white bars). (a) Immunoblots corresponding to mature LOX (mLOX; left panel) & LOX-PP (right panel) are shown. The position of the pro-enzyme (ProLOX, right panel), detected with the antibody against the propeptide, was also indicated. GAPDH was analyzed as a loading control. Displayed blots are not cropped from different gels or different parts of the same gel & images conform the digital image & integrity policies of the journal. Representative immunoblots from 3 independent experiments were shown. (b) Transduced VSMC were serum-starved for 24 h & then stimulated with 20% FCS. Cell proliferation was evaluated by the [3H]-thymidine incorporation method (left panel) or by cell count (right panel) in these cells. Results represented as mean ± SD. *P < 0.003 vs. pLVX (Kruskal-Wallis; at least n = 6). (c) [3H]-thymidine incorporation into DNA assessed in human VSMC transduced with lentiviral particles for full-length LOX (pLOX; black bars), or the corresponding empty vector (pLVX; white bars) treated or not with BAPN (500 µM). Results are represented as mean ± SD. P < 0.0001: * vs. pLVX; #vs. pLOX transduced cells (Two-way ANOVA; at least n = 9). Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30185869), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-41568_rabbit-polyclonal-lox-propeptide-antibody-31020241624915.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0012.jpg "Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of GSK-3 beta in mouse beta cell line (betaTC3) using anti-GSK-3 beta antibody. Image from verified customer review.")
![Immunocytochemistry/Immunofluorescence: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of NIH/3T3 (left) and U251 (right) cells using GSK3 beta mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunocytochemistry-Immunofluorescence-NBP1-47470-img0006.jpg)
![Immunohistochemistry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas and GSK-3 beta in a murine xenograft model. SW620 cells injected into flanks of athymic Nude mice & tumor volume was checked biweekly. Mice treated weekly with oxaliplatin (days 0, 7 and 14) & injected daily with Fap1 blocking SLV peptide, VLS control peptide, or treated with SLV or VLS peptide alone (n=12). Tumors were simultaneously harvested when control tumors were >2,000 mm3. SLV peptide increases Gsk3-phosphorylation with/without oxaliplatin. IF detection of total versus phospho- GSK-3 beta performed with DAPI staining of nuclei (areas without gland formation were selected). Image collected and cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.25401), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-NBP1-47470-img0014.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - An intracellular stain was performed on HeLa cells with GSK-3 beta (3D10) antibody NBP1-47470PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerythrin.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0013.jpg)
![Western Blot: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis using GSK3 beta mouse mAb against A549 (1), K562 (2), PC-12 (3), NIH/3T3 (4), and HEK293 (5) cell lysates.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Western-Blot-NBP1-47470-img0008.jpg)
![Immunohistochemistry-Paraffin: GSK-3 beta Antibody (3D10) [NBP1-47470] - Analysis of paraffin-embedded human lung cancer (left) and breast cancer tissues (right) using GSK3 beta mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Immunohistochemistry-Paraffin-NBP1-47470-img0007.jpg)
![Flow Cytometry: GSK-3 beta Antibody (3D10) [NBP1-47470] - Flow cytometric analysis of Hela cells using GSK3 beta mouse mAb (green) and negative control (purple).](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Flow-Cytometry-NBP1-47470-img0005.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple Western lane view shows a specific band for GSK-3 Beta in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0009.jpg)
![Simple Western: GSK-3 beta Antibody (3D10) [NBP1-47470] - Simple western analysis of mouse brain tissue (striatum) from 4 month old Tg4150 and wildtype mice. Image courtesy of Dr. Brandi Wasek-Patterson at Baylor Research Institute, Institute of Metabolic Disease.](http://images.novusbio.com/fullsize/GSK-3-beta-Antibody-3D10-Simple-Western-NBP1-47470-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases Fas & Gsk3 beta phosphorylation in CD133+ cells in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases Fas phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Fas or CD133 was performed with DAPI staining of nuclei. (B) SLV peptide increases Gsk3 beta phosphorylation in CD133+ xenograft tumors with or without oxaliplatin. Immunofluorescent detection of phospho-Gsk3 beta or CD133 was performed with DAPI staining of nuclei. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-310202416171462.jpg)
![Immunocytochemistry/ Immunofluorescence: GSK-3 beta Antibody (3D10) - BSA Free [NBP1-47470] - Fap1-inhibition with SLV peptide increases phosphorylation of Fap1-substrates Fas & Gsk3 beta in a murine xenograft modelSW620 cells were injected in the flanks of athymic Nude mice & tumor volume was determination biweekly. Mice were treated weekly with oxaliplatin (days 0, 7 & 14) & injected daily with Fap1 blocking SLV peptide or VLS control peptide, or treated with SLV or VLS peptide alone (n=12 per cohort). Tumors were simultaneously harvested from cohorts of mice when control tumors were >2,000 mm3. (A) SLV peptide increases gland formation in xenograft tumors with or without oxaliplatin. Histology was analyzed by hematoxylin/ eosin staining. Fap1 expression was determined by immunofluorescence. Relative fluorescent intensity (RFI) of Fap1 staining is indicated below relevant panels. (B) SLV peptide increases Fas-phosphorylation in xenograft tumors with or without by oxaliplatin. Immunofluorescent detection of total versus phospho-Fas was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. (C) SLV peptide increases Gsk3 beta -phosphorylation with or without oxaliplatin. Immunofluorescent detection of total versus phospho- Gsk3 beta was performed with DAPI staining of nuclei. Areas without gland formation were selected for this study. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29899829), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-47470_mouse-monoclonal-gsk-3-beta-antibody-3d10-3102024161604.jpg)